Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial [PDF]
EBioMedicine, 2020 Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Shreeya Tewary +13 more
doaj +3 more sources
Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +20 more sources
Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease [PDF]
Clinical and Molecular Hepatology, 2018 Background/Aims Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of ...
Saba Sayari +2 more
doaj +1 more source
Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor. [PDF]
PLoS ONE, 2015 Sitagliptin (SG) increases serum GLP-1 (Glucagon-like peptide-1) through inhibition of the hormone degradation. Resistant starch (RS) induces GLP-1 expression by stimulating L-cells in the intestine.
Felicia Goldsmith +9 more
doaj +1 more source
Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study. [PDF]
Diabetes Obes MetabMochizuki K +3 more
europepmc +3 more sources
Frontiers in Endocrinology, 2022 PurposeDipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients.
Xingchun Wang +6 more
doaj +1 more source
Changes in carotid intima‐media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima‐Media Thickness Evaluation [PDF]
, 2017 Type 2 diabetes mellitus is a risk factor for cardiovascular disease. Both the absolute value and progression of carotid artery intima‐media thickness (IMT) are considered a marker of progression of atherosclerosis.
Tomoya Mita +7 more
openalex +4 more sources
Frontiers in Endocrinology, 2023 BackgroundDiabetes has become a serious global public health problem. With the increasing prevalence of type 2 diabetes mellitus (T2DM), the incidence of complications of T2DM is also on the rise.
Jian-hong Qi +6 more
doaj +1 more source
An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles
Applied Sciences, 2018 Sitagliptin (MK-0431), is a potent oral hypoglycemic drug that is used for treating type 2 diabetes mellitus. However, the short half-life of sitagliptin requires patients to take a high dose of 50 mg twice per day, and the fraction of sitagliptin ...
Afzal Haq Asif +3 more
doaj +1 more source
Attenuation of acrylamide-induced neurotoxicity by supplementation of sitagliptin in Wistar rats [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Acrylamide (ACR) induces neurotoxicity in humans and animals through different mechanisms. Sitagliptin is a type-2 diabetes medication with neuroprotective properties.
Mahboobeh Navabi +3 more
doaj +1 more source